Comparing the biological impact of glatiramer acetate with the biological impact of a generic von Towfic, Fadi, Funt, Jason M, Fowler, Kevin D, Bakshi, Shlomo, Blaugrund, Eran, Artyomov, Maxim N, Hayden, Michael R, Ladkani, David, Schwartz, Rivka, Zeskind, Benjamin

Volltext

Once‐daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis von Yamamura, Takashi, Ashtamker, Natalia, Ladkani, David, Fukazawa, Toshiyuki, Houzen, Hideki, Tanaka, Masami, Miura, Toshiro, Knappertz, Volker

Volltext

Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study von Achiron, Anat, Givon, Uri, Magalashvili, David, Dolev, Mark, Liraz Zaltzman, Sigal, Kalron, Alon, Stern, Yael, Mazor, Zeev, Ladkani, David, Barak, Yoram

Volltext

Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research von Grossman, Iris, Knappertz, Volker, Laifenfeld, Daphna, Ross, Colin, Zeskind, Ben, Kolitz, Sarah, Ladkani, David, Hayardeny, Liat, Loupe, Pippa, Laufer, Ralph, Hayden, Michael

Volltext

Bayesian analysis of glatiramer acetate 40 mg/mL TIW treatment effect in reducing relapse rate (P3.416) von Barnett-Griness, Ofra, Noble, Robert, Steinerman, Joshua, Alexander, Jessica, Ladkani, David

Volltext

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial von Wolinsky, Jerry S., Narayana, Ponnada A., O'Connor, Paul, Coyle, Patricia K., Ford, Corey, Johnson, Kenneth, Miller, Aaron, Pardo, Lillian, Kadosh, Shaul, Ladkani, David

Volltext

Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition von Hasson, Tal, Kolitz, Sarah, Towfic, Fadi, Laifenfeld, Daphna, Bakshi, Shlomo, Beriozkin, Olga, Shacham-Abramson, Maya, Timan, Bracha, Fowler, Kevin D, Birnberg, Tal, Konya, Attila, Komlosh, Arthur, Ladkani, David, Hayden, Michael R, Zeskind, Benjamin, Grossman, Iris

Volltext

Long-term MRI follow-up of patients in the ALLEGRO study: results from the yearly frequent MRI sub-cohort (P7.258) von Rocca, Maria, Galantucci, Sebastiano, Dadon, Yuval, Gorfine, Tali, Ladkani, David, Sasson, Nissim, Comi, Giancarlo, Filippi, Massimo

Volltext

Effect of Alfacalcidol on Fatigue in MS Patients: A Randomized, Double-Blind Study (S23.004) von Barak, Yoram, Magalashvili, David, Dolev Dolgopiat, Mark, Ladkani, David, Nitzani, Dalia, Mazor, Zeev, Achiron, Anat

Volltext

Rationale For Advancing Laquinimod For Progressive MS: Evidence From Large Clinical Trials In RRMS (S4.001) von Comi, Giancarlo, Sormani, Maria Pia, Giovannoni, Gavin, Ladkani, David, Sasson, Nissim, Gorfine, Talia, Knappertz, Volker

Volltext

Mediation of the Effect of Laquinimod on Disability Progression in Relapsing-Remitting Multiple Sclerosis (RRMS) (P3.195) von Comi, Giancarlo, Ladkani, David, Vollmer, Timothy, Sormani, Maria Pia, Sidi, Yulia, Knappertz, Volker

Volltext

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree von Cutter, Gary R, Knappertz, Volker, Sasson, Nissim, Ladkani, David

Volltext

The glatiramoid class of immunomodulator drugs von Varkony, Haim, Weinstein, Vera, Klinger, Ety, Sterling, Jeffrey, Cooperman, Helena, Komlosh, Turi, Ladkani, David, Schwartz, Rivka

Volltext

Glatiramer acetate treatment in PPMS: Why males appear to respond favorably von Wolinsky, Jerry S, Shochat, Tzippy, Weiss, Sivan, Ladkani, David

Volltext

Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids von Kolitz, Sarah, Hasson, Tal, Towfic, Fadi, Funt, Jason M., Bakshi, Shlomo, Fowler, Kevin D., Laifenfeld, Daphna, Grinspan, Augusto, Artyomov, Maxim N., Birnberg, Tal, Schwartz, Rivka, Komlosh, Arthur, Hayardeny, Liat, Ladkani, David, Hayden, Michael R., Zeskind, Benjamin, Grossman, Iris

Volltext

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients von Ford, C C, Johnson, K P, Lisak, R P, Panitch, H S, Shifroni, G, Wolinsky, J S

Volltext

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials von Boneschi, Filippo Martinelli, Rovaris, Marco, Johnson, Kenneth P, Miller, Aaron, Wolinsky, Jerry S, Ladkani, David, Shifroni, Galia, Comi, Giancarlo, Filippi, Massimo

Volltext

Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic: e83757 von Towfic, Fadi, Funt, Jason M, Fowler, Kevin D, Bakshi, Shlomo, Blaugrund, Eran, Artyomov, Maxim N, Hayden, Michael R, Ladkani, David, Schwartz, Rivka, Zeskind, Benjamin

Volltext

Short-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis von Rovaris, Marco, Comi, Giancarlo, Ladkani, David, Wolinsky, Jerry S, Filippi, Massimo

Volltext

Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis von Rovaris, Marco, Comi, Giancarlo, Sormani, Maria Pia, Wolinsky, Jerry S., Ladkani, David, Filippi, Massimo

Volltext